Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Medical Oncology
Published in: Medical Oncology 1/2015

01-01-2015 | Original Paper

Sonic hedgehog–Gli1 signals promote epithelial–mesenchymal transition in ovarian cancer by mediating PI3K/AKT pathway

Authors: Zhang Ke, Sun Caiping, Zhang Qing, Wang Xiaojing

Published in: Medical Oncology | Issue 1/2015

Login to get access

Abstract

Epithelial–mesenchymal transition (EMT) has been reported to play an important role in distant metastasis in cancer-related disease. A large number of studies have shown that sonic hedgehog–glioma-associated oncogene 1 (Shh–Gli1) signals participate in the process of EMT; however, the role and mechanism of Shh–Gli1 signals in the progression of EMT in ovarian cancer remain largely unknown. First, we investigated the occurrence of EMT and invasion and migration ability in ovarian cancer cells stimulated by different concentration of Shh–Gli1 signals agonist purmorphamine in vitro. Then, Akt siRNA was transfected into ovarian cancer cells which already stimulated by purmorphamine to elucidate the molecular mechanism underlying the pathogenesis of EMT in ovarian cancer. Gli1 expression was significantly enhanced in ovarian cancer cells after stimulated by purmorphamine. In addition, Gli1 up-regulation promoted EMT, invasion and migration ability of ovarian cancer cells. Furthermore, we validated a cross talk between Shh–Gli1 signals and PI3K–Akt pathway in the occurrence of EMT in ovarian cancer cells. These findings revealed a novel role for Shh–Gli1 signals in EMT in ovarian cancer and provided for us a potential therapeutic target for the suppression of EMT, invasion and metastasis in ovarian cancer.
Literature
1.
Tan TZ, Miow QH, Miki Y, Noda T, Mori S, Huang RY, Thiery JP. Epithelial–mesenchymal transition spectrum quantification and its efficacy in deciphering survival and drug responses of cancer patients. EMBO Mol Med. 2014;6(10):1279–93.PubMedCentralPubMedCrossRef
2.
Wang Y, Hu C, Dong R, Huang X, Qiu H. Platelet-derived growth factor-D promotes ovarian cancer invasion by regulating matrix metalloproteinases 2 and 9. Asian Pac J Cancer Prev. 2011;12(12):3367–70.PubMed
3.
Wang Y, Ma J, Shen H, Wang C, Sun Y, Howell SB, Lin X. Reactive oxygen species promote ovarian cancer progression via the HIF-1α/LOX/E-cadherin pathway. Oncol Rep. 2014;32(5):2150–8.PubMed
4.
Wang WS, Yang XS, Xia M, Jiang HY, Hou JQ. Silencing of twist expression by RNA interference suppresses epithelial–mesenchymal transition, invasion, and metastasis of ovarian cancer. Asian Pac J Cancer Prev. 2012;13(9):4435–9.PubMedCrossRef
5.
Law AY, Wong CK. Stanniocalcin-2 promotes epithelial–mesenchymal transition and invasiveness in hypoxic human ovarian cancer cells. Exp Cell Res. 2010;316(20):3425–34.PubMedCrossRef
6.
Yun SJ, Kim WJ. Role of the epithelial–mesenchymal transition in bladder cancer: from prognosis to therapeutic target. Korean J Urol. 2013;54(10):645–50.PubMedCentralPubMedCrossRef
7.
Xu X, Su B, Xie C, Wei S, Zhou Y, Liu H, Dai W, Cheng P, Wang F, Xu X, Guo C. Sonic hedgehog–Gli1 signaling pathway regulates the epithelial mesenchymal transition (EMT) by mediating a new target gene, S100A4, in pancreatic cancer cells. PLoS One. 2014;9(7):e96441.PubMedCentralPubMedCrossRef
8.
Sun XD, Liu XE, Huang DS. Curcumin reverses the epithelial–mesenchymal transition of pancreatic cancer cells by inhibiting the Hedgehog signaling pathway. Oncol Rep. 2013;29(6):2401–7.PubMed
9.
Clark AR, Toker A. Signalling specificity in the Akt pathway in breast cancer. Biochem Soc Trans. 2014;42(5):1349–55.PubMedCrossRef
10.
Xu X, Zhou Y, Xie C, Wei SM, Gan H, He S, Wang F, Xu L, Lu J, Dai W, He L, Chen P, Wang X, Guo C. Genome-wide screening reveals an EMT molecular network mediated by sonic hedgehog–Gli1 signaling in pancreatic cancer cells. PLoS One. 2012;7(8):e43119.PubMedCentralPubMedCrossRef
11.
Wang ZM, Lu YK, Han Y, Jiang JY, Yuan XD. Dipeptidyl peptidase IV gene expression in ovarian carcinoma cell lines with various malignant behaviour. Acta Academiae Medicinae Sinicae. 2005;27(2):205–10.PubMed
12.
Hua F, Xia Y, Wang H, Chen R, Ren Y, Yang J, Liang W. Effects of small interfering RNA silencing MACC-1 expression on cell proliferation, cell cycle and invasion ability of cervical cancer SiHa cells. Zhonghua Zhong Liu Za Zhi. 2014;36(7):496–500.PubMed
13.
Wolff F, Loipetzberger A, Gruber W, Esterbauer H, Aberger F, Frischauf AM. Imiquimod directly inhibits Hedgehog signalling by stimulating adenosine receptor/protein kinase A-mediated GLI phosphorylation. Oncogene. 2013;32(50):5574–81.PubMedCentralPubMedCrossRef
14.
Davidson B, Rosenfeld YB, Holth A, Hellesylt E, Tropé CG, Reich R, Yisraeli JK. VICKZ2 protein expression in ovarian serous carcinoma effusions is associated with poor survival. Hum Pathol. 2014;45(7):1520–8.PubMedCrossRef
15.
Oue T, Uehara S, Yamanaka H, Nomura M, Usui N. Hedgehog signal inhibitors suppress the invasion of human rhabdomyosarcoma cells. Pediatr Surg Int. 2013;29(11):1153–8.PubMedCentralPubMedCrossRef
16.
Javelaud D, Pierrat MJ, Mauviel A. Crosstalk between TGF-β and hedgehog signaling in cancer. FEBS Lett. 2012;586(14):2016–25.PubMedCrossRef
17.
Yanai K, Nakamura M, Akiyoshi T, Nagai S, Wada J, Koga K, Noshiro H, Nagai E, Tsuneyoshi M, Tanaka M, Katano M. Crosstalk of hedgehog and Wnt pathways in gastric cancer. Cancer Lett. 2008;263(1):145–56.PubMedCrossRef
18.
Min S, Xiaoyan X, Fanghui P, Yamei W, Xiaoli Y, Feng W. The glioma-associated oncogene homolog 1 promotes epithelial–mesenchymal transition in human esophageal squamous cell cancer by inhibiting E-cadherin via snail. Cancer Gene Ther. 2013;20(7):379–85.PubMedCrossRef
19.
Busch EL, McGraw KA, Sandler RS. The potential for markers of epithelial–mesenchymal transition to improve colorectal cancer outcomes: a systematic review. Cancer Epidemiol Biomark Prev. 2014;23(7):1164–75.CrossRef
20.
Xuan X, Zeng Q, Li Y, Gao Y, Wang F, Zhang H, Wang Z, He H, Li S. Akt-mediated transforming growth factor-β1-induced epithelial–mesenchymal transition in cultured human esophageal squamous cancer cells. Cancer Gene Ther. 2014;21(6):238–45.PubMedCrossRef
21.
Kuo SZ, Blair KJ, Rahimy E, Kiang A, Abhold E, Fan JB, Wang-Rodriguez J, Altuna X, Ongkeko WM. Salinomycin induces cell death and differentiation in head and neck squamous cell carcinoma stem cells despite activation of epithelial-mesenchymal transition and Akt. BMC Cancer. 2012;12:556–63.PubMedCentralPubMedCrossRef
Metadata
Title
Sonic hedgehog–Gli1 signals promote epithelial–mesenchymal transition in ovarian cancer by mediating PI3K/AKT pathway
Authors
Zhang Ke
Sun Caiping
Zhang Qing
Wang Xiaojing
Publication date
01-01-2015
Publisher
Springer US
Published in
Medical Oncology / Issue 1/2015
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-014-0368-y

Other articles of this Issue 1/2015

Medical Oncology 1/2015 Go to the issue

Original Paper

Overexpression of cyclin D1 in meningioma is associated with malignancy grade and causes abnormalities in apoptosis, invasion and cell cycle progression

Original Paper

Prognostic value of differential CCND1 expression in patients with resected gastric adenocarcinoma

Original Paper

Correlation between epidermal growth factor receptor and tumor stem cell markers CD44/CD24 and their relationship with prognosis in breast invasive ductal carcinoma

Letter to the Editor

Occurrence of BCR/ABL fusion gene in a patient with acute promyelocytic leukemia

Original Paper

Topo2A as a prognostic biomarker for patients with resectable esophageal squamous cell carcinomas

Original Paper

Intratumoral chemotherapy with paclitaxel liposome combined with systemic chemotherapy: a new method of neoadjuvant chemotherapy for stage III unresectable non-small cell lung cancer
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits